New Juvederm Voluma XC Receives FDA Approval

Last fall, Allergan, a leader in medical aesthetics, conducted an extensive clinical trial of Juvederm Voluma XC that proved its safety and effectiveness. The U.S. Food and Drug Administration (FDA) approved the filler to temporarily correct age-related volume loss in adults over the age of 21. Juvederm Voluma XC is the first and only filler to gain approval and claims to boost cheeks and overall facial volume with results lasting up to two years. It offers a non-surgical option for clients seeking additional lift in the cheek area to compensate for the loss of volume that occurs naturally over time. "As people age, the cheek area can lose volume, causing the cheeks to flatten out and the skin to droop and sag," says Derek H. Jones, Ph.D., associate professor of dermatology at UCLA, founder and medical director at Skin Care and Laser Physicians of Beverly Hills (CA), and clinical investigator in the Juvederm Voluma XC study. "In the Juvederm Voluma XC clinical trial, physicians and patients were able to see instant and visible results, including correction of age-related volume loss in the cheek area."

Suggested Articles

Crown is now poised to become a global leader in dermatology health and wellness.

Holly Cutler shares her expert thoughts on what to expect from medical spas in 2020.

Allergan Aesthetics will operate as a new business with its own research and development function under the AbbVie umbrella.